Researchers studying defective protein in search of cystic fibrosis treatment

March 28, 2012 By Johanna VanderMaas
Ryerson researcher Russell Viirre is leading a research team that is examining the defective protein that causes cystic fibrosis in order to ultimately create stronger drugs for treating the disease.

(Medical Xpress) -- Cystic fibrosis is the most common fatal genetic disease affecting Canadian children and young adults, more than two children each and every week are diagnosed with cystic fibrosis (CF). New research at Ryerson University, in partnership with The Hospital for Sick Children, is examining the interaction between lab-tested drugs and the defective protein that causes CF to understand how and why the drugs work and to create stronger, more powerful second generation drugs to treat CF.

Cystic fibrosis is caused by a that would normally create a protein called transmembrane conductance regulator protein (), which is involved with regulating the content of salt and water in mucous. When the gene is defective, have thicker, stickier mucous that builds up in the lungs as well as other organs. Symptoms include , difficulty breathing and trouble with digestion. Ultimately, CF is fatal.

Russell Viirre is a synthetic organic chemist and a professor in Ryerson University’s Department of Chemistry and Biology whose research focuses on synthesizing molecular probes to study the detective protein that causes CF with the hope of creating new drugs to treat it. 

“We’re looking at drugs that can interact with the defective protein, essentially restoring it to its native function,” says Viirre. “In other words, helping the defective protein behave like it’s supposed to.”

According to Viirre, fixing the defective protein should eliminate the symptoms of CF. As part of their research, Viirre and his team are examining the structures of failed drugs that, in a previous lab setting fixed the defective protein but for a variety of reasons, never made it to patient trials.  The team modifies the structure of the drug slightly and in such a way that biochemists can examine how each of the failed drugs interacts with the defective protein.  Once modified, the drug is brought to SickKids Hospital where the research group of collaborator Christine Bear, Senior Scientist in SickKids’ Molecular Structure & Function Program, conducts further testing. Experiments carried out there determine if the modified drug repairs the defective protein.

“We’re making molecular probes to help pinpoint the position and the nature of the interaction between the drug and the protein” says Viirre. “The Bear group at SickKids uses these probes to try to find the site on the protein where a particular drug binds.”

A recent paper published by the research team for the Journal of Medicinal Chemistry describes the first successful batch of these probes, based on one particular drug. The paper identifies what part of the drug molecule the team was able to change.

Viirre likens their work to that of finding out how a key fits in a lock.

“Once we know what the key hole looks like, we can make a key that fits that hole better,” says Viirre. “The idea is that the better the key fits, the more powerful and successful the CF treatment will be.”

Viirre and his collaborators have identified approximately a dozen previously tested drugs and the team will study each of them. Within the next five years, they will start to get answers about the and how it interacts with these drugs, which will ultimately give them the information needed for the creation of stronger, more effective drugs for the treatment of CF.  

Synthesis and Properties of Molecular Probes for the Rescue Site on Mutant Cystic Fibrosis Transmembrane Conductance Regulator was published in the December 22, 2011 issue of the Journal of Medicinal Chemistry and was funded by the Canadian Institutes of Health Research and Cystic Fibrosis Canada. The article can be downloaded free of charge at

Explore further: Cystic fibrosis drug reverses genetic abnormality in the CF mutation

Related Stories

Unraveling a new regulator of cystic fibrosis

September 19, 2011

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR). ...

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...

Food-poisoning bacteria may be behind Crohn's disease

October 19, 2016

People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study led by researchers at McMaster University.

Neurodevelopmental model of Zika may provide rapid answers

October 19, 2016

A newly published study from researchers working in collaboration with the Regenerative Bioscience Center at the University of Georgia demonstrates fetal death and brain damage in early chick embryos similar to microcephaly—a ...

Scientists uncover new facets of Zika-related birth defects

October 17, 2016

In a study that could one day help eliminate the tragic birth defects caused by Zika virus, scientists from the Florida campus of The Scripps Research Institute (TSRI) have elucidated how the virus attacks the brains of newborns, ...

Ebola drug ZMapp may help, but is not a miracle cure

October 13, 2016

ZMapp, once touted as a miraculous "secret serum" against the deadly Ebola virus, has shown some success but fell short of the bar for effectiveness in a clinical trial, researchers said Wednesday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.